FDA Approves OXALIPLATIN — Accord Healthcare Inc.

# FDA Approves Generic Oxaliplatin from Accord Healthcare Inc. Accord Healthcare Inc. received FDA approval for a generic version of oxaliplatin, an intravenous chemotherapy drug, marking another competitive entry into the colorectal cancer treatment market and potentially lowering treatment costs for patients. The approval of the ANDA application could intensify price competition among oxaliplatin manufacturers and expand patient access to this widely-used platinum-based chemotherapy agent.